Pharminent

Sofosbuvir/velpatasvir improved patient-reported outcomes, knocked out HCV genotypes 1-6

AT THE LIVER MEETING 2016 BOSTON (FRONTLINE MEDICAL NEWS) – When given with ribavirin, a fixed-dose combination of sofosbuvir/velpatasvir (Epclusa) achieved a sustained viral response at 12 weeks (SVR-12) in 94% of decompensated cirrhotic patients with hepatitis C virus (HCV) genotypes 1-6 infection, according to Zobair M. Younossi, MD. Patients with and without cirrhosis also […] https://www.pm360online.com/sofosbuvirvelpatasvir-improved-patient-reported-outcomes-knocked-out-hcv-genotypes-1-6/

Filed under: HCV